Phaseline

Companies › AgonOx

AgonOx: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DP CD8 TIL
Autologous CD8+ tumor infiltrating lymphocytes enriched for CD39+CD103+ cells, expanded ex
–Phase 1HNSCCDec 2026
DP CD8 TIL KD
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 1HNSCCDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05902520DP CD8 TILPhase 1HNSCCOncologyDec 2026
NCT05902520DP CD8 TIL KDPhase 1HNSCCOncologyDec 2026

Targets

IL2RA (1) IL2RG (1) IL2RB (1)

Companies with the same targets

CellTrans Sanofi ImmunityBio Nektar Therapeutics Regeneron Pharmaceuticals Mural Oncology PolTREG GI Innovation Synthekine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.